Scott Robertson has served as a member of our board of directors since September 2023. Mr. Robertson currently serves as the Chief Financial Officer and Chief Business Officer of Star Therapeutics, Inc., a biotechnology company, since January 2024. Mr. Robertson also served as the Chief Business and Financial Officer of DICE Therapeutics, Inc. (Nasdaq: DICE), a biotechnology company, from July 2021 to December 2023 (including following the company's acquisition by Eli Lilly and Company in August 2023), the Chief Financial Officer from December 2017 to July 2021, and as the Vice President, Business Development & Strategic Planning from April 2016 to December 2017. He previously served as a Lecturer at the Haas School of Business at the University of California, Berkeley and as a member of the board of directors of Hexima Limited (ASX: HXL), a biotechnology company, from December 2018 to September 2023. Mr. Robertson received his B.S. in Business Administration from the University of Southern California and his M.B.A. from the Haas School of Business at the University of California, Berkeley. We believe Mr. Robertson s extensive executive and business experience with life sciences companies qualifies him to serve on our board of directors.